N/A N=35

Multi-Center Evaluation of Feasibility of SPECT Measurement of Myocardial Blood Flow and Reserve

Coronary Artery Disease

Bottom Line

View on ClinicalTrials.gov: NCT03427749 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Apr 2025

Primary outcome: Primary: Correlation in MBF Between Core Laboratory and Local Site — 0.93 correlation coefficient

Study Design & Population

Study type: Observational
Phase: N/A
Interventions: SPECT Imaging with 99mTc-Tetrofosmin Research Imaging (Diagnostic_test)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Ottawa Heart Institute Research Corporation
Primary completion: Oct 2022

Outcome Measures

Outcome	Result	p-value
PRIMARY Correlation in MBF Between Core Laboratory and Local Site	0.93	—
SECONDARY Impact on Throughput	72.28	—

Summary

Patients will be recruited from those referred to the local site's Diagnostic Imaging Department for SPECT myocardial perfusion imaging (MPI) ,who have an intermediate to high pre-test likelihood of disease (Diamond-Forrester criteria ≥ 30%) and are clinically indicated to have an MBF study.

Eligibility Criteria

Inclusion Criteria

Age ≥ 18 years old
BMI ≤ 40 kg/m2
Able and willing to comply with the study procedures
Written informed consent
Intermediate to high probability of CAD
Suspected or known CAD on a stable medication regime

Exclusion Criteria

History or risk of severe bradycardia (heart rate < 50 beats per minute) not related to chronotropic drugs
Known second- or third-degree AV block without pacemaker
Dyspnea (NYHA III/IV), wheezing asthma or COPD
Coronary artery bypass graft (CABG) surgery within 60 days prior to screening or within 45 days after consent (early revascularization)
Percutaneous coronary intervention (PCI) within 30 days prior to screening or within 45 days following consent (early revascularization)
Recent use of dipyridamole, dipyridamole-containing medications (e.g. Aggrenox)
Known hypersensitivity to dipyridamole or adenosine
Breastfeeding or pregnancy
Claustrophobia or inability to lie still in a supine position
Unwillingness or inability to provide informed consent

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03427749). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.